US pharmaceutical giant Pfizer has offered what it said would be its bid to acquire UK rival AstraZeneca, but its $119 billion proposal was turned down.
Reports say AstraZeneca rejected the bid just hours after it was introduced by Pfizer, despite Pfizer’s deadline for AstraZeneca to respond to the bid by May 26.
In a statement, AstraZeneca described the latest offer as a “minor improvement” from the last, which was made for $106 billion.
Despite the rejection, reports say Pfizer was not optimistic ahead of submitting its bid, and said it would not make a hostile takeover offer to AstraZeneca shareholders. In a statement, Pfizer CEO Ian Read said the company does not believe “that the AstraZeneca board is currently prepared to recommend a deal at a reasonable price.” The company added that it would remain open to further dialogue with the UK firm.
The merger would have created the world’s largest pharmaceutical company.’’
Full content: Yahoo News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canadian School Boards Sue Social Media Giants for $4 Billion
Mar 28, 2024 by
CPI
Alaska Airlines and Hawaiian Airlines Enter Timing Agreement with DOJ
Mar 28, 2024 by
CPI
Sam Bankman-Fried Gets 25-Year Sentence for $8B Crypto Fraud
Mar 28, 2024 by
CPI
Walmart Withdraws and Refiles Antitrust Review Application for Vizio Acquisition
Mar 28, 2024 by
CPI
Apple Prevails in Dismissal of Crypto-Payment Antitrust Lawsuit
Mar 27, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI